Receptor Tyrosine Protein Kinase ERBB 3 market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Receptor Tyrosine Protein Kinase ERBB 3 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Receptor Tyrosine Protein Kinase ERBB 3 market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
BA-0702
CDX-3379
Elgemtumab
ETBX-031
Others
Segment by Application
Non-Small Cell Carcinoma
Solid Tumor
Melanoma
Colorectal Cancer
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Etubics Corporation
F. Hoffmann-La Roche Ltd.
GamaMabs Pharma S.A.
GlaxoSmithKline Plc
Hanmi Pharmaceuticals, Co. Ltd.
ImmunoGen, Inc.
Kolltan Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc.
Merus B.V.
Novartis AG
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Sihuan Pharmaceutical Holdings Group Ltd.
Sorrento Therapeutics, Inc.
Symphogen A/S
Takis S.r.l.